Neutral Dr Reddy's Laboratories, target Rs 3070: Credit Suisse
The global brokerage firm expects competition in Metoprolol and Decitabine over 12-18 months. Some clarity on Copaxone will come from Patent review decision.
By 
| Updated:
| Updated: Credit Suisse maintains a neutral rating on Dr Reddy's Laboratories with a 12-month target price of Rs 3070. The profit concentration in the US is still high with top 4 products contributing 35 per cent of FY18 profits.
The global investment bank expects the near-term competition in two of these products. On Fondaparinux, Credit Suisse expects Teva & Aurobindo to enter in six months.
The global brokerage firm expects competition in Metoprolol and Decitabine over 12-18 months. Some clarity on Copaxone will come from Patent review decision.
The global investment bank expects the near-term competition in two of these products. On Fondaparinux, Credit Suisse expects Teva & Aurobindo to enter in six months.
The global brokerage firm expects competition in Metoprolol and Decitabine over 12-18 months. Some clarity on Copaxone will come from Patent review decision.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced2026-05-12T11:28:57Z- Buy, Sell or Hold: DAM Capital initiates coverage on Orkla India; Citi maintains sell on Dr Reddy's Laboratories2026-04-15T04:33:57Z
- Dr Reddy's Laboratories Q3 Results: Profit falls 14% YoY to Rs 1,210 crore, revenue up 4%2026-01-21T11:42:20Z
ADVERTISEMENT
